Next Article in Journal
History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs
Previous Article in Journal
Measurement of Respiratory Chain Enzyme Activity in Human Renal Biopsy Specimens
Previous Article in Special Issue
Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
Correction published on 20 November 2017, see J. Clin. Med. 2017, 6(11), 106.
Open AccessReview

Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan
Academic Editor: Marco Ladetto
J. Clin. Med. 2017, 6(10), 91; https://doi.org/10.3390/jcm6100091
Received: 30 April 2017 / Revised: 17 September 2017 / Accepted: 20 September 2017 / Published: 25 September 2017
(This article belongs to the Special Issue Role of Minimal Residual Disease Assessment in Hematological Cancers)
Multiple myeloma (MM) is a hematological malignancy with a poor prognosis, characterized by clonal proliferation of plasma cells in the bone marrow (BM). Relapse due to undetected minimal residual disease (MRD) is the leading cause of death among patients with MM. This review summarizes the methods and prognostic value of MRD assessment in BM and autografts from MM patients who underwent autologous stem cell transplantation (ASCT) by multiparameter flow cytometry (MFC), allele-specific oligonucleotide real-time quantitative PCR (ASO-qPCR), droplet digital PCR (ddPCR), and next-generation sequencing (NGS)-based detection methods. MRD assessment using NGS-based approaches has clear prognostic value and better sensitivity compared to traditional methods. View Full-Text
Keywords: multiple myeloma; minimal residual disease; allele-specific oligonucleotide-PCR; droplet digital PCR; next-generation sequencing multiple myeloma; minimal residual disease; allele-specific oligonucleotide-PCR; droplet digital PCR; next-generation sequencing
Show Figures

Figure 1

MDPI and ACS Style

Takamatsu, H. Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation. J. Clin. Med. 2017, 6, 91.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop